CERo Therapeutics Stock (NASDAQ:CERO)

Revenue Financials Chart

Previous Close

$8.11

52W Range

$6.71 - $896.00

50D Avg

$8.70

200D Avg

$74.25

Market Cap

$9.56M

Avg Vol (3M)

$1.13M

Beta

0.49

Div Yield

-

CERO Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Nov 30, 2021

Website

CERO Performance

CERO Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-16.20M	$-2.93M	$-2.91M
Net Income	$-11.09M	$-2.54K	$-667.74K
EBITDA	$-16.20M	$-2.44M	$-68.58K
Basic EPS	-	$-0.39	$-0.10
Diluted EPS	-	$-0.39	$-0.10

Fiscal year ends in Dec 24 | Currency in USD